Unravelling soluble (pro)renin receptor-mediated endothelial dysfunction.

Area of Science:

• Reproductive biology
• Vascular biology
• Endocrinology

Background:

• Preeclampsia is linked to maternal endothelial dysfunction and hypertension.
• Elevated soluble prorenin receptor (s(P)RR) levels are observed in preeclamptic pregnancies.
• Recombinant s(P)RR causes hypertension and vascular dysfunction.

Purpose of the Study:

• To investigate the effects of PRO20, an s(P)RR antagonist, on s(P)RR-induced endothelial dysfunction.
• To examine the interaction between s(P)RR, PRO20, and the Angiotensin II Type 1 Receptor (AT1R).

Main Methods:

• Human uterine microvascular endothelial cells (HUtMECs) were treated with s(P)RR, PRO20, Losartan (AT1R antagonist), or Aliskerin (renin inhibitor).
• Endothelial dysfunction markers were assessed via immunoblot, qPCR, and ELISA.
• Protein structure prediction and molecular docking were used to model s(P)RR-AT1R interactions.

Main Results:

• PRO20 reduced s(P)RR-induced mRNA expression of endothelin-1, VCAM-1, and ICAM-1.
• PRO20 prevented s(P)RR and preeclamptic serum-induced protein increases in endothelin-1 and VCAM-1.
• Molecular modeling indicated PRO20 impairs s(P)RR-AT1R complex formation.

Conclusions:

• Elevated s(P)RR contributes to endothelial dysfunction, partly via AT1R.
• PRO20 inhibits s(P)RR-AT1R complex formation.
• PRO20 shows therapeutic potential for preeclampsia and related conditions.